LC/MS/MS Method Package for Modified Nucleosides

Significance of the Topic

Modified nucleosides, degradation products of enzymatically altered RNAs, are excreted in urine and circulate in blood. Their quantitation has emerged as a valuable biomarker in infectious disease research, including severity assessment in COVID-19 patients. Rapid and robust analytical methods are essential to support clinical and research laboratories in monitoring these biomarkers.

Study Objectives and Overview

This method package aims to deliver a complete LC–MS/MS solution for quantifying two specific modified nucleosides—N6-threonyl-carbamoyladenosine (t6A) and its 2-methylthio analog (ms2t6A)—along with normalization factors in serum and urine. Key goals include:

• Establishing a fast chromatographic separation (six-minute runtime).
• Optimizing mass spectrometric detection parameters for trace analysis.
• Providing validated sample preparation protocols for blood serum and urine.

Methodology and Instrumentation

Sample Preparation:

• Protein precipitation and solid-phase extraction steps tailored for serum and urine matrices.
• Internal standards added to correct for extraction efficiency and matrix effects.

Chromatographic Conditions:

• Reversed-phase LC column and gradient optimized for baseline separation of modified nucleosides and endogenous controls within six minutes.
• High-throughput setup enabling analysis of large sample batches.

Mass Spectrometric Parameters and Instrumentation:

• Triple quadrupole systems (Shimadzu LCMS-8000 series or LCMS-8060NX) configured in MRM mode.
• IonFocus lenses on LCMS-8060NX to reduce matrix contamination and extend maintenance intervals.
• LabSolutions LCMS software (ver. 5.99 SP2 or later) for data acquisition and processing.

Main Results and Discussion

The method demonstrated reliable quantitation of t6A and ms2t6A in both serum and urine, with linear calibration ranges covering expected clinical concentrations. Chromatographic peaks exhibited sharp resolution and minimal carryover. Matrix effects were effectively controlled through internal standard normalization. Analysis time per sample was under six minutes, delivering high throughput without sacrificing sensitivity.

Benefits and Practical Applications

This comprehensive package reduces method development time, allowing laboratories to implement validated assays immediately. Practical applications include:

• Clinical research on COVID-19 severity biomarkers.
• Monitoring of other infectious diseases and metabolic disorders.
• Routine QA/QC in diagnostic and pharmaceutical labs.

Future Trends and Potential Applications

Advances may include automation of sample preparation, multiplexed detection of broader modified nucleoside panels, and integration with high-resolution MS for structural elucidation. Expanded applications could address emerging viral infections and personalized medicine strategies.

Conclusion

The presented LC–MS/MS method package delivers a fast, robust, and user-friendly workflow for the quantitation of key modified nucleosides in biofluids. Its implementation supports both clinical research and industrial analytics, facilitating biomarker discovery and routine monitoring.

Reference

Tomizawa K. et al. Patent pending, Japanese application No. 2021-038698.